These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3121342)

  • 1. Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia.
    Eriksson M; Angelin B
    Eur J Clin Invest; 1987 Oct; 17(5):396-401. PubMed ID: 3121342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
    von Bergmann K; Leiss O
    Eur J Clin Invest; 1984 Apr; 14(2):150-4. PubMed ID: 6428905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1984 Feb; 14(1):73-8. PubMed ID: 6421601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1981 Jun; 11(3):185-9. PubMed ID: 6791937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids.
    Odman B; Ericsson S; Lindmark M; Berglund L; Angelin B
    Eur J Clin Invest; 1991 Jun; 21(3):344-9. PubMed ID: 1909637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary lipid composition in normo- and hyperlipoproteinemia.
    Ahlberg J; Angelin B; Einarsson K; Hellström K; Leijd B
    Gastroenterology; 1980 Jul; 79(1):90-4. PubMed ID: 7380228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary lipids in familial combined hyperlipidaemia: effects of acipimox therapy.
    Ericsson S; Eriksson M; Angelin B
    Eur J Clin Invest; 1990 Jun; 20(3):261-5. PubMed ID: 2114986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B; Einarsson K; Leijd B
    Clin Sci Mol Med; 1978 Apr; 54(4):451-5. PubMed ID: 639478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary lipid composition during treatment with different hypolipidaemic drugs.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.
    Raedsch R; Plachky J; Wolf N; Simonis G
    Eur J Drug Metab Pharmacokinet; 1995; 20(2):113-8. PubMed ID: 8582435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid treatment in humans: effects on plasma and biliary lipid metabolism with special reference to very low density lipoprotein triglyceride and bile acid kinetics.
    Angelin B; Nilsell K; Einarsson K
    Eur J Clin Invest; 1986 Apr; 16(2):169-77. PubMed ID: 3089812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
    Tesone PA; Gladstein J; Acuña AM
    Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.